Agenus to Present BOT/BAL Tumor Inflammation Biomarker Data at AACR-IO
Agenus will present new data at the AACR-IO conference in April 2026 exploring systemic and tumor inflammation biomarkers with its BOT/BAL bispecific antibody therapy in immunologically cold tumors. Preliminary findings on BOT/BAL biomarker correlations may guide patient stratification and combination strategies to enhance immune responses in tumors resistant to existing checkpoint inhibitors.
1. Data Presentation at AACR-IO
Agenus will feature new preclinical and early clinical data on its BOT/BAL bispecific antibody at the AACR-IO conference in April 2026. The presentation will detail systemic and intratumoral inflammation biomarker analyses in immunologically cold tumor models, highlighting correlations with treatment response.
2. Potential Clinical Implications
The biomarker findings aim to inform patient selection criteria and optimal combination regimens to overcome resistance in tumors with low immune infiltration. By identifying key inflammation markers, Agenus intends to refine clinical trial designs and accelerate development pathways for BOT/BAL.
3. Next Steps for BOT/BAL Development
Following the conference presentation, Agenus plans to integrate the biomarker insights into upcoming Phase 1/2 studies. The company will assess combination approaches with checkpoint inhibitors and other immunomodulators to validate the predictive value of identified biomarkers.